| 1 |
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol 2023. [PMID: 36964768 DOI: 10.1007/s00330-023-09518-y] [Reference Citation Analysis]
|
| 2 |
Prado-Wohlwend S, Ballesta-Moratalla M, Torres-Espallardo I, Del Olmo-García MI, Bello-Arques P, Olivas-Arroyo C, Merino-Torres JF. Same-day comparative protocol PET/CT-PET/MRI [(68) Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine. Cancer Imaging 2023;23:4. [PMID: 36627700 DOI: 10.1186/s40644-023-00521-6] [Reference Citation Analysis]
|
| 3 |
Beyer T, Czernin J, Freudenberg L, Giesel F, Hacker M, Hicks RJ, Krause BJ. A 2022 International Survey on the Status of Prostate Cancer Theranostics. J Nucl Med 2023;64:47-53. [PMID: 35953304 DOI: 10.2967/jnumed.122.264298] [Reference Citation Analysis]
|
| 4 |
Serfling SE, Hartrampf PE, Zhi Y, Higuchi T, Rowe SP, Bundschuh L, Essler M, Buck AK, Bundschuh RA, Werner RA. Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy. Clin Nucl Med 2022. [PMID: 35439187 DOI: 10.1097/RLU.0000000000004189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Serfling SE, Lapa C, Dreher N, Hartrampf PE, Rowe SP, Higuchi T, Schirbel A, Weich A, Hahner S, Fassnacht M, Buck AK, Werner RA. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. Mol Imaging Biol. [DOI: 10.1007/s11307-022-01717-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Prado-wohlwend S, Bernal-vergara J, Utrera-costero A, Cañón-sánchez J, Agudelo-cifuentes M, Bello-arques P. Terapia con péptidos radiomarcados con [177Lu]Lu-DOTA-TATE. Revista Española de Medicina Nuclear e Imagen Molecular 2022;41:55-65. [DOI: 10.1016/j.remn.2021.11.001] [Reference Citation Analysis]
|
| 8 |
Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
|
| 9 |
Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 2021;:e13040. [PMID: 34668262 DOI: 10.1111/jne.13040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Narrative review of generative adversarial networks in medical and molecular imaging. Ann Transl Med 2021;9:821. [PMID: 34268434 DOI: 10.21037/atm-20-6325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 11 |
Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 12 |
Has Simsek D, Kuyumcu S, Karadogan S, Oflas M, Isik EG, Ozkan ZG, Paksoy N, Ekmekcioglu O, Ekenel M, Sanli Y. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? Ann Nucl Med 2021;35:680-90. [PMID: 33783752 DOI: 10.1007/s12149-021-01610-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 13 |
Ruggeri V. Médecine nucléaire – quels enjeux futurs, en particulier technologiques et pharmaceutiques ? Médecine Nucléaire 2020;44:298-304. [DOI: 10.1016/j.mednuc.2020.09.005] [Reference Citation Analysis]
|
| 14 |
Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, Schulz S, Higuchi T, Buck AK, Bengel FM, Bundschuh RA, Lapa C. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. J Nucl Med 2021;62:514-20. [PMID: 32859702 DOI: 10.2967/jnumed.120.245464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 16 |
Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro Oncol 2019;21:585-95. [PMID: 30615138 DOI: 10.1093/neuonc/noz003] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 29.3] [Reference Citation Analysis]
|
| 17 |
Simsek DH, Sanli Y, Engin MN, Erdem S, Sanli O. Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification. Eur J Nucl Med Mol Imaging 2021;48:1639-49. [DOI: 10.1007/s00259-020-04995-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, Kuyumcu S. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer? Ann Nucl Med 2020;34:476-85. [PMID: 32394269 DOI: 10.1007/s12149-020-01474-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2020;47:2339-47. [PMID: 32157427 DOI: 10.1007/s00259-020-04718-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 20 |
Galldiks N, Suchorska B, Albert NL, Tonn JC. Metabolic Imaging of Brain Metastasis. Central Nervous System Metastases 2020. [DOI: 10.1007/978-3-030-23417-1_13] [Reference Citation Analysis]
|
| 21 |
Kinuya S. An appreciation from the out-going editor-in-chief. Ann Nucl Med 2019;33:875-6. [DOI: 10.1007/s12149-019-01423-z] [Reference Citation Analysis]
|
| 22 |
Lapa C. Exciting Opportunities in Nuclear Medicine Imaging and Therapy. J Clin Med 2019;8:E1944. [PMID: 31718092 DOI: 10.3390/jcm8111944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 23 |
Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 2019;8:E1060. [PMID: 31331016 DOI: 10.3390/jcm8071060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 24 |
Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine 2019;49:255-70. [DOI: 10.1053/j.semnuclmed.2019.02.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 25 |
Kinuya S. Activities for the Development of Targeted Radionuclide Therapy in Japan. Nucl Med Mol Imaging 2019;53:35-7. [PMID: 30828398 DOI: 10.1007/s13139-018-0563-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP. Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med 2019;60:577-84. [PMID: 30796171 DOI: 10.2967/jnumed.118.223537] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 27 |
Chalouhy C, Gurram S, Ghavamian R. Current controversies on the role of lymphadenectomy for prostate cancer. Urol Oncol 2019;37:219-26. [PMID: 30579787 DOI: 10.1016/j.urolonc.2018.11.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 28 |
Kazuhiro K, Werner RA, Toriumi F, Javadi MS, Pomper MG, Solnes LB, Verde F, Higuchi T, Rowe SP. Generative Adversarial Networks for the Creation of Realistic Artificial Brain Magnetic Resonance Images. Tomography 2018;4:159-63. [PMID: 30588501 DOI: 10.18383/j.tom.2018.00042] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 29 |
Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
|
